Financings in Brief: Medical Science Systems, Inc.
This article was originally published in The Gray Sheet
Medical Science Systems, Inc.: Initial public offering of 1.5 mil. shares at $8-9 each is outlined in a filing with the Securities and Exchange Commission. The Newport Beach, California genetic disease susceptibility testing services firm plans to use anticipated proceeds for the launch of genetic testing services for periodontitis, osteoporosis, coronary artery disease and diabetic retinopathy. Nutmeg Securities is the underwriter for the offering...
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.